Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:330054OMIM:613076G71.3
Who is this for?
Show terms as
1FDA treatments8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome is an extremely rare genetic condition that affects multiple body systems from birth or early infancy. The name describes its main features: babies are born with cloudy lenses in their eyes (congenital cataracts), experience progressively worsening low muscle tone (muscular hypotonia), develop hearing loss, and show delays in reaching developmental milestones such as sitting, walking, and speaking. This condition falls under the broader category of mitochondrial or neuromuscular disorders, as reflected by its ICD-10 classification under mitochondrial myopathy (G71.3), suggesting that problems with how cells produce energy may play a role in the disease. Because this syndrome affects the eyes, muscles, ears, and brain development simultaneously, children with this condition typically need care from multiple specialists. The cataracts can impair vision from a very early age if not treated surgically. The progressive muscle weakness can affect movement, feeding, and breathing over time. Hearing loss may range from mild to severe and can further complicate speech and language development. There is currently no cure for this syndrome. Treatment focuses on managing each symptom individually — cataract surgery to restore vision, hearing aids or cochlear implants for hearing loss, physical therapy for muscle weakness, and early intervention programs to support developmental progress. Because so few cases have been described in the medical literature, the full spectrum of the disease and its long-term outlook are still being understood.

Also known as:

Key symptoms:

Cloudy lenses in the eyes present at birth (cataracts)Low muscle tone that gets worse over timeHearing lossDelayed development of motor skills like sitting and walkingDelayed speech and language developmentDifficulty feeding in infancyMuscle weaknessPoor balance and coordinationIntellectual disability or learning difficultiesReduced visionFloppy or limp body in infancyFatigue and low energy levels

Clinical phenotype terms (13)— hover any for plain English
Progressive sensorineural hearing impairmentHP:0000408Rotary nystagmusHP:0001583Decreased circulating ferritin concentrationHP:0012343Abnormal muscle fiber protein expressionHP:0030089
Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

1 event
Feb 2009

ATryn: FDA approved

Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients.

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

ATryn

recombinant human antithrombin· GTC Biotherapeutics, Inc.Orphan Drug

Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients.

No actively recruiting trials found for Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome community →

No specialists are currently listed for Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndromeForum →

No community posts yet. Be the first to share your experience with Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome.

Start the conversation →

Latest news about Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome

No recent news articles for Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What genetic testing has been done, and do we know the exact genetic cause of my child's condition?,When should cataract surgery be performed, and what are the risks and expected outcomes?,What type of hearing loss does my child have, and what are the best options for hearing support?,How quickly might the muscle weakness progress, and what can we do to slow it down?,What therapies and early intervention services should we start right away?,Are there any clinical trials or research studies that my child might be eligible for?,Should other family members be tested, and what is the chance of this happening in future pregnancies?

Common questions about Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome

What is Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome?

Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome is an extremely rare genetic condition that affects multiple body systems from birth or early infancy. The name describes its main features: babies are born with cloudy lenses in their eyes (congenital cataracts), experience progressively worsening low muscle tone (muscular hypotonia), develop hearing loss, and show delays in reaching developmental milestones such as sitting, walking, and speaking. This condition falls under the broader category of mitochondrial or neuromuscular disorders, as reflected

At what age does Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome typically begin?

Typical onset of Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome is neonatal. Age of onset can vary across affected individuals.

What treatment and support options exist for Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome?

1 patient support program are currently tracked on UniteRare for Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome. See the treatments and support programs sections for copay assistance, eligibility, and contact details.